Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

XTalks

JANUARY 22, 2025

Valneva SE, who developed the worlds first FDA-approved chikungunya vaccine , has now unveiled promising Phase III data for its single-shot chikungunya vaccine, IXCHIQ, in adolescents aged 12 to 17. The study included 754 adolescents, comparing immune responses and safety profiles between vaccine and placebo groups.

Immune Response 59

Immune Response Vaccination Vaccine Trials 59

Pharmaceutical Technology

FEBRUARY 6, 2023

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263

Protein Research Antibody Immune Response 263

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246

Pharmaceutical Technology

NOVEMBER 16, 2022

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

XTalks

NOVEMBER 12, 2024

November is Pancreatic Cancer Awareness Month , a time dedicated to increasing public understanding of this challenging disease, supporting patients and their families and advancing research for better treatment options. For this reason, researchers are working hard to find new methods to identify pancreatic cancer sooner.

Research 105

Research FDA Approval Trials Clinical Trials 105

BioPharma Reporter

OCTOBER 11, 2022

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

Immune Response 116

Immune Response Vaccination Vaccine Clinical Trials 116

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. But there are concerns that Russia has rushed development of the vaccine to claim a political victory in the race to get a vaccine approved.

Immune Response 107

Immune Response Vaccination Vaccine Trials 107

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

Immune Response 80

Immune Response Protein Vaccination Vaccine 80

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting.

Development 162

Development Life Science Immune Response Trials 162

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). This blocks a cascade of responses that are induced by interleukin-25 (IL-25), a critical cytokine which is classified as ‘alarmin’. “As

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.

Immune Response 71

Immune Response Vaccination Vaccine Development 71

Scienmag

APRIL 16, 2021

Credit: (C) Erica Tandori Researchers within the Biomedicine Discovery Institute at Monash University have made a breakthrough in understanding the role played by high-risk immune genes associated with the development of rheumatoid arthritis (RA).

Immune Response 97

Immune Response Gene Research Development 97

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

Pharmaceutical Technology

MAY 12, 2023

Absci has collaborated with the University of Oxford’s Kennedy Institute of Rheumatology to expedite the development of AI-driven immunotherapies. The company will then reassemble the antigen-antibody pairs, using its reverse immunology approach, as starting points for the development of drugs.

Development 130

Development Antibody Immune Response Genome 130

XTalks

APRIL 1, 2025

We are thrilled with the results from the EQUATOR study, which mark a major milestone in the development of itolizumab as a first-line treatment option for aGVHD, said Bruce Steel, CEO of Equillium, in the companys news release.

Immune Response 94

Immune Response Trials Licensing Licensing 94

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. A herpesvirus family member, CMV is spread through body fluids.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

APRIL 28, 2023

Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 15, 2023

New generation of monoclonal antibodies (bi-specific antibodies) are considered active immunotherapies because they link immune cells and cancer cells to activate anti-cancer immune response. Immatics undertakes the discovery of targets for cancer immunotherapies with the development of the right T-cell receptors.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

JUNE 23, 2022

According to findings from a pivotal study, a four-dose paediatric regimen of Vaxneuvance induced immune responses non-inferior to the presently available 13-valent pneumococcal conjugate vaccine (PCV13) for the 13 shared serotypes.

Vaccination 147

Vaccination Vaccine Immune Response Clinical Trials 147

Pharmaceutical Technology

JUNE 16, 2023

The developer has tested OVX836 in four completed clinical trials. In a company statement announcing the latest trial kick-off, Osivax said a recently completed separate Phase IIa trial demonstrated that the candidate in combination with QIVs had a good safety profile with no impairment of immune response by the QIVs.

Vaccination 246

Vaccination Vaccine Trials Immune Response 246

Scienmag

APRIL 1, 2021

Early life exposure to antibotics in utero and through mother’s milk disrupts beneficial gut bacteria, compromising T-cell development, Rutgers research shows Exposure to antibiotics in utero and infancy can lead to an irreversible loss of regulatory T-cells in the colon-a valuable component of the immune system’s response toward allergens (..)

Immune Response 75

Immune Response Allergies Bacteria Development 75

Scienmag

OCTOBER 13, 2021

Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have developed macrophage–tumor chimeric exosomes that co-activate the immune response and tumor microenvironment to support cancer immunotherapy.

Immune Response 52

Immune Response Engineer Development Research 52

Pharma Mirror

OCTOBER 16, 2023

by Carrie Taylor, Director of Research & Development of BOCSCI. Globally, the COVID-19 pandemic has significantly accelerated the development of mRNA technology platforms and mRNA industry chains.

Immune Response 130

Immune Response Drugs Protein Vaccination 130

Camargo

JULY 27, 2021

How and When to Incorporate PK Design into Your Gene Therapy Development Plan. While most gene therapy clinical studies are ongoing, a number of products are in advanced clinical development, and several are approved by FDA. PK Planning for Gene Therapy Development Programs. Exposure-Response Considerations.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Scienmag

JUNE 3, 2021

Strong immune responses to unchanging, conserved parts of the 2009 H1N1 pandemic flu virus suggest strategies for effective universal vaccines Credit: Guthmiller et al.

Immune Response 98

Immune Response Vaccination Vaccine Development 98

XTalks

NOVEMBER 15, 2024

MDS are a group of blood disorders caused by abnormal development of blood cells in the bone marrow. This progression occurs when the abnormal cells in the bone marrow increase uncontrollably, leading to the development of a more aggressive form of blood cancer. “We

Trials 105

Trials HR Immune Response FDA Approval 105

Pharmaceutical Technology

JULY 5, 2022

Furthermore, equity holders of TeneoTwo are entitled to get up to $805m in research and development (R&D)-based milestone payments as well as up to $360m as commercial-related milestone payments from AstraZeneca. As per the deal, AstraZeneca will make an upfront payment of $100m on the closing of the transaction.

Immune Response 147

Immune Response Gene Therapy Gene Development 147

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. Other efforts to develop a nasally-delivered COVID-19 vaccine have met with greater success.

Vaccination 116

Vaccination Vaccine Immune Response Development 116

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Immune Response 52

Immune Response Development Medicine Drugs 52

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. Currently, most vaccine designs and testing focus on creating a systemic immune response to prevent disease or death. million deaths every year.

Vaccination 116

Vaccination Vaccine Immune Response Bacteria 116

XTalks

APRIL 18, 2022

Top COVID-19 mRNA vaccine maker BioNTech is setting out to explore new and improved delivery technologies for mRNA vaccines, recently announcing a collaboration with New Jersey-based lipid nanocrystal developer Matinas BioPharma. Under the deal, BioNTech will give Matinas BioPharma an upfront exclusive access fee and research funding.

Vaccination 105

Vaccination Vaccine Development Immune Response 105

XTalks

NOVEMBER 12, 2024

Thus, to address drug-resistant infections, pharma and biotech companies are developing novel treatments such as bacteriophage therapies, immunomodulators and monoclonal antibodies. Collaborative efforts, from research and development to public health interventions, are important for addressing the challenges posed by this disease.

Bacteria 110

Bacteria Life Science Vaccination Vaccine 110

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Further scientific research into the virus and recognition that it was not like influenza A, a flu virus known to cause bronchitis, would transpire over the next 30 years. .

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303